文献速递淋巴瘤造血干细胞移植与细胞治疗

抗CD30 CAR-T细胞疗法治疗复发和难治性霍奇金淋巴瘤

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
PubMed 文献 · J Clin Oncol · 2020-07-23

两项平行I/II期研究在2个独立中心纳入复发或难治性霍奇金淋巴瘤患者,淋巴清除后输注CD30.CAR-T细胞,主要终点为安全性。41例患者中细胞因子释放综合征10例均为1级,无神经毒性;接受氟达拉滨为基础淋巴清除的32例活动性疾病患者总缓解率72%,完全缓解19例(59%)。

要点

  • 41例复发或难治性霍奇金淋巴瘤患者接受CD30.CAR-T细胞输注,中位既往治疗线数为7线。
  • 最常见毒性为3级或以上血液学不良事件;细胞因子释放综合征10例均为1级,无神经毒性。
  • 接受氟达拉滨为基础淋巴清除的32例活动性疾病患者总缓解率72%,完全缓解19例(59%)。

核心结论

  • 既往接受大量治疗的复发或难治性霍奇金淋巴瘤患者接受氟达拉滨为基础淋巴清除后输注CD30.CAR-T细胞,获得高比例持久缓解且安全性良好,提示CAR-T细胞疗法可扩展至经典B细胞恶性肿瘤之外。

研究设计与样本

  • 2项平行I/II期研究(ClinicalTrials.gov标识:NCT02690545和NCT02917083),在2个独立中心纳入复发或难治性霍奇金淋巴瘤患者,淋巴清除方案为苯达莫司汀单药、苯达莫司汀联合氟达拉滨或环磷酰胺联合氟达拉滨,主要终点为安全性。

主要发现

  • 41例患者接受CD30.CAR-T细胞输注,既往治疗中位7线(范围2-23),包括维布妥昔单抗、检查点抑制剂及自体或异基因干细胞移植。
  • 最常见毒性为3级或以上血液学不良事件;细胞因子释放综合征见于10例患者,均为1级;未观察到神经毒性。
  • 接受氟达拉滨为基础淋巴清除的32例活动性疾病患者总缓解率为72%,其中19例(59%)达完全缓解。
  • 中位随访533天,所有可评估患者1年无进展生存率为36%(95%CI,21%至51%),总生存率为94%(95%CI,79%至99%)。
  • CAR-T细胞体内扩增呈细胞剂量依赖性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Chimeric antigen receptor (CAR) T-cell therapy of B-cell malignancies has proved to be effective. We show how the same approach of CAR T cells specific for CD30 (CD30.CAR-Ts) can be used to treat Hodgkin lymphoma (HL). METHODS: We conducted 2 parallel phase I/II studies (ClinicalTrials.gov identifiers: NCT02690545 and NCT02917083) at 2 independent centers involving patients with relapsed or refractory HL and administered CD30.CAR-Ts after lymphodepletion with either bendamustine alone, bendamustine and fludarabine, or cyclophosphamide and fludarabine. The primary end point was safety. RESULTS: Forty-one patients received CD30.CAR-Ts. Treated patients had a median of 7 prior lines of therapy (range, 2-23), including brentuximab vedotin, checkpoint inhibitors, and autologous or allogeneic stem cell transplantation. The most common toxicities were grade 3 or higher hematologic adverse events. Cytokine release syndrome was observed in 10 patients, all of which were grade 1. No neurologic toxicity was observed. The overall response rate in the 32 patients with active disease who received fludarabine-based lymphodepletion was 72%, including 19 patients (59%) with complete response. With a median follow-up of 533 days, the 1-year progression-free survival and overall survival for all evaluable patients were 36% (95% CI, 21% to 51%) and 94% (95% CI, 79% to 99%), respectively. CAR-T cell expansion in vivo was cell dose dependent. CONCLUSION: Heavily pretreated patients with relapsed or refractory HL who received fludarabine-based lymphodepletion followed by CD30.CAR-Ts had a high rate of durable responses with an excellent safety profile, highlighting the feasibility of extending CAR-T cell therapies beyond canonical B-cell malignancies.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ramos CA, Grover NS, Beaven AW, et al. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol. 2020. PMID: 32701411. doi:10.1200/JCO.20.01342

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。